GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » Quick Ratio

Nxera Pharma Co (Nxera Pharma Co) Quick Ratio : 3.62 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Nxera Pharma Co's quick ratio for the quarter that ended in Dec. 2023 was 3.62.

Nxera Pharma Co has a quick ratio of 3.62. It generally indicates good short-term financial strength.

The historical rank and industry rank for Nxera Pharma Co's Quick Ratio or its related term are showing as below:

SOLTF' s Quick Ratio Range Over the Past 10 Years
Min: 0.42   Med: 7.01   Max: 36.05
Current: 3.62

During the past 13 years, Nxera Pharma Co's highest Quick Ratio was 36.05. The lowest was 0.42. And the median was 7.01.

SOLTF's Quick Ratio is ranked better than
51% of 1551 companies
in the Biotechnology industry
Industry Median: 3.51 vs SOLTF: 3.62

Nxera Pharma Co Quick Ratio Historical Data

The historical data trend for Nxera Pharma Co's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Quick Ratio Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.49 14.08 8.73 17.08 3.62

Nxera Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.08 20.42 15.35 3.09 3.62

Competitive Comparison of Nxera Pharma Co's Quick Ratio

For the Biotechnology subindustry, Nxera Pharma Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Quick Ratio falls into.



Nxera Pharma Co Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Nxera Pharma Co's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(452.225-20.162)/119.356
=3.62

Nxera Pharma Co's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(452.225-20.162)/119.356
=3.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nxera Pharma Co  (OTCPK:SOLTF) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Nxera Pharma Co Quick Ratio Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co (Nxera Pharma Co) Business Description

Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (Nxera Pharma Co) Headlines

From GuruFocus